Rose Capital Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$932K Sell
32,688
-4,892
-13% -$130K 0.23% 87
2026
Q2
$905K Buy
+37,580
New +$983K 0.45% 42

Other funds holding PFE

Rose Capital Advisors's PFE Position: Q3 2026 in Review

Rose Capital Advisors reduced its Pfizer (PFE) stake by 13% in Q3 2026, selling an estimated $130K and leaving 32,688 shares worth $932K. The position accounts for 0.23% of the portfolio, ranked #87.

Rose Capital Advisors first reported a position in PFE in Q2 2026 and has held it in 2 quarters since. 2,916 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Rose Capital Advisors held 32,688 shares of Pfizer worth $932K as of Q3 2026.
  • Rose Capital Advisors sold 4,892 Pfizer shares in Q3 2026, an estimated $130K.
  • Pfizer made up 0.23% of Rose Capital Advisors's portfolio in Q3 2026, its #87 holding.
  • Rose Capital Advisors first reported a position in Pfizer in Q2 2026 and has held it in 2 quarters since.
  • 2,916 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Rose Capital Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.